Literature DB >> 11123375

Use of trifluoroperazine isolates a [(3)H]Ifenprodil binding site in rat brain membranes with the pharmacology of the voltage-independent ifenprodil site on N-methyl-D-aspartate receptors containing NR2B subunits.

L L Coughenour1, B M Barr.   

Abstract

The use of trifluoroperazine in a well washed rat brain membrane preparation revealed [(3)H]ifenprodil binding to a single high affinity state with the pharmacology of N-methyl-D-aspartate (NMDA) receptors containing NR2B subunits. Inhibition of [(3)H]ifenprodil binding in the presence of trifluoroperazine by 10 NR1a/NR2B selective agents was highly correlated with their inhibition at rat NR1a/NR2B receptors expressed in Xenopus ooctyes and [(3)H]TCP binding to rat brain NR2B subunit containing NMDA receptors but not with their inhibition of [(3)H]DTG binding. Allosteric interactions with polyamines, Mg(2+), Zn(2+), glutamate, glycine, and their antagonists were consistent with NMDA receptors with NR2B subtype pharmacology. The rank order of polyamine inhibition was spermine > spermidine > 1,5-(diethylamino)piperidine > arcaine > agmatine > putrescine. Both spermidine and MgCl(2) shifted the inhibition curve of ifenprodil to the right in a parallel manner, but Mg(2+) did not appear to be additive to spermidine. Glutamate increased and glycine decreased the binding. Conversely, CPP decreased the binding, and MDL 105,519 increased the binding in an agonist reversible manner. The increase with MDL 105,519 and glutamate appeared to be additive as did the decrease with glycine and CPP. Changes in the buffer pH between 6.5 and 8.0 did not affect the affinity of NR2B agents. Cirazoline but not clonidine inhibited the binding. MK-801 and agents from various other pharmacological classes did not significantly inhibit [(3)H]ifenprodil binding. [(3)H]Ifenprodil binding in the presence of trifluoroperazine appears to be selective for the voltage-independent ifenprodil site on NMDA receptors containing the NR2B subunit.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11123375

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  The micromolar zinc-binding domain on the NMDA receptor subunit NR2B.

Authors:  Julie Rachline; Florent Perin-Dureau; Anne Le Goff; Jacques Neyton; Pierre Paoletti
Journal:  J Neurosci       Date:  2005-01-12       Impact factor: 6.167

2.  Low concentrations of neuroactive steroids alter kinetics of [3H]ifenprodil binding to the NMDA receptor in rat frontal cortex.

Authors:  Tobias Johansson; Per-Anders Frändberg; Fred Nyberg; Pierre Le Grevès
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

3.  Endogenous zinc in neurological diseases.

Authors:  Jae-Yong Koh
Journal:  J Clin Neurol       Date:  2005-10-20       Impact factor: 3.077

Review 4.  The glutamatergic system and Alzheimer's disease: therapeutic implications.

Authors:  D Allan Butterfield; Chava B Pocernich
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

5.  Novel conjugates of aminoadamantanes with carbazole derivatives as potential multitarget agents for AD treatment.

Authors:  Sergey O Bachurin; Elena F Shevtsova; Galina F Makhaeva; Vladimir V Grigoriev; Natalia P Boltneva; Nadezhda V Kovaleva; Sofya V Lushchekina; Pavel N Shevtsov; Margarita E Neganova; Olga M Redkozubova; Elena V Bovina; Alexey V Gabrelyan; Vladimir P Fisenko; Vladimir B Sokolov; Alexey Yu Aksinenko; Valentina Echeverria; George E Barreto; Gjumrakch Aliev
Journal:  Sci Rep       Date:  2017-03-30       Impact factor: 4.379

6.  Exploring the overlapping binding sites of ifenprodil and EVT-101 in GluN2B-containing NMDA receptors using novel chicken embryo forebrain cultures and molecular modeling.

Authors:  Marthe F Fjelldal; Thibaud Freyd; Linn M Evenseth; Ingebrigt Sylte; Avi Ring; Ragnhild E Paulsen
Journal:  Pharmacol Res Perspect       Date:  2019-05-30

7.  Conjugates of γ-Carbolines and Phenothiazine as new selective inhibitors of butyrylcholinesterase and blockers of NMDA receptors for Alzheimer Disease.

Authors:  Galina F Makhaeva; Sofya V Lushchekina; Natalia P Boltneva; Vladimir B Sokolov; Vladimir V Grigoriev; Olga G Serebryakova; Ekaterina A Vikhareva; Alexey Yu Aksinenko; George E Barreto; Gjumrakch Aliev; Sergey O Bachurin
Journal:  Sci Rep       Date:  2015-08-18       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.